Literature DB >> 23108159

Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy.

Hiroaki Mitsuhashi1, Satomi Mitsuhashi, Taylor Lynn-Jones, Genri Kawahara, Louis M Kunkel.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is a common form of muscular dystrophy characterized by an asymmetric progressive weakness and wasting of the facial, shoulder and upper arm muscles, frequently accompanied by hearing loss and retinal vasculopathy. FSHD is an autosomal dominant disease linked to chromosome 4q35, but the causative gene remains controversial. DUX4 is a leading candidate gene as causative of FSHD. However, DUX4 expression is extremely low in FSHD muscle, and there is no DUX4 animal model that mirrors the pathology in human FSHD. Here, we show that the misexpression of very low levels of human DUX4 in zebrafish development recapitulates the phenotypes seen in human FSHD patients. Microinjection of small amounts of human full-length DUX4 (DUX4-fl) mRNA into fertilized zebrafish eggs caused asymmetric abnormalities such as less pigmentation of the eyes, altered morphology of ears, developmental abnormality of fin muscle, disorganization of facial musculature and/or degeneration of trunk muscle later in development. Moreover, DUX4-fl expression caused aberrant localization of myogenic cells marked with α-actin promoter-driven enhanced green fluorescent protein outside somite boundary, especially in head region. These abnormalities were rescued by coinjection of the short form of DUX4 (DUX4-s). Our results suggest that the misexpression of DUX4-fl, even at extremely low level, can recapitulate the phenotype observed in FSHD patients in a vertebrate model. These results strongly support the current hypothesis for a role of DUX4 in FSHD pathogenesis. We also propose that DUX4 expression during development is important for the pathogenesis of FSHD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23108159      PMCID: PMC3606007          DOI: 10.1093/hmg/dds467

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  39 in total

1.  Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy.

Authors:  C Wijmenga; J E Hewitt; L A Sandkuijl; L N Clark; T J Wright; H G Dauwerse; A M Gruter; M H Hofker; P Moerer; R Williamson
Journal:  Nat Genet       Date:  1992-09       Impact factor: 38.330

2.  Enhanced expression and stable transmission of transgenes flanked by inverted terminal repeats from adeno-associated virus in zebrafish.

Authors:  C D Hsiao; F J Hsieh; H J Tsai
Journal:  Dev Dyn       Date:  2001-04       Impact factor: 3.780

Review 3.  Facioscapulohumeral muscular dystrophy.

Authors:  Rabi Tawil; Silvère M Van Der Maarel
Journal:  Muscle Nerve       Date:  2006-07       Impact factor: 3.217

4.  Early onset facioscapulohumeral muscular dystrophy.

Authors:  O F Brouwer; G W Padberg; E Bakker; C Wijmenga; R R Frants
Journal:  Muscle Nerve Suppl       Date:  1995

5.  On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy.

Authors:  G W Padberg; O F Brouwer; R J de Keizer; G Dijkman; C Wijmenga; J J Grote; R R Frants
Journal:  Muscle Nerve Suppl       Date:  1995

6.  Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy.

Authors:  J E Hewitt; R Lyle; L N Clark; E M Valleley; T J Wright; C Wijmenga; J C van Deutekom; F Francis; P T Sharpe; M Hofker
Journal:  Hum Mol Genet       Date:  1994-08       Impact factor: 6.150

7.  Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element.

Authors:  J Gabriëls; M C Beckers; H Ding; A De Vriese; S Plaisance; S M van der Maarel; G W Padberg; R R Frants; J E Hewitt; D Collen; A Belayew
Journal:  Gene       Date:  1999-08-05       Impact factor: 3.688

8.  DNA rearrangements in Japanese facioscapulohumeral muscular dystrophy patients: clinical correlations.

Authors:  K Goto; J H Lee; C Matsuda; K Hirabayashi; T Kojo; A Nakamura; Y Mitsunaga; T Furukawa; K Sahashi; K Arahata
Journal:  Neuromuscul Disord       Date:  1995-05       Impact factor: 4.296

9.  Removal of dystroglycan causes severe muscular dystrophy in zebrafish embryos.

Authors:  Michael J Parsons; Isabel Campos; Elizabeth M A Hirst; Derek L Stemple
Journal:  Development       Date:  2002-07       Impact factor: 6.868

10.  Pax-3 is necessary for migration but not differentiation of limb muscle precursors in the mouse.

Authors:  G Daston; E Lamar; M Olivier; M Goulding
Journal:  Development       Date:  1996-03       Impact factor: 6.868

View more
  39 in total

1.  The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1.

Authors:  Sabrina Sacconi; Richard J L F Lemmers; Judit Balog; Patrick J van der Vliet; Pauline Lahaut; Merlijn P van Nieuwenhuizen; Kirsten R Straasheijm; Rashmie D Debipersad; Marianne Vos-Versteeg; Leonardo Salviati; Alberto Casarin; Elena Pegoraro; Rabi Tawil; Egbert Bakker; Stephen J Tapscott; Claude Desnuelle; Silvère M van der Maarel
Journal:  Am J Hum Genet       Date:  2013-09-26       Impact factor: 11.025

2.  Human skeletal muscle xenograft as a new preclinical model for muscle disorders.

Authors:  Yuanfan Zhang; Oliver D King; Fedik Rahimov; Takako I Jones; Christopher W Ward; Jaclyn P Kerr; Naili Liu; Charles P Emerson; Louis M Kunkel; Terence A Partridge; Kathryn R Wagner
Journal:  Hum Mol Genet       Date:  2014-01-22       Impact factor: 6.150

Review 3.  Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease.

Authors:  Charis L Himeda; Takako I Jones; Peter L Jones
Journal:  Antioxid Redox Signal       Date:  2014-12-04       Impact factor: 8.401

4.  AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD.

Authors:  Carlee R Giesige; Lindsay M Wallace; Kristin N Heller; Jocelyn O Eidahl; Nizar Y Saad; Allison M Fowler; Nettie K Pyne; Mustafa Al-Kharsan; Afrooz Rashnonejad; Gholamhossein Amini Chermahini; Jacqueline S Domire; Diana Mukweyi; Sara E Garwick-Coppens; Susan M Guckes; K John McLaughlin; Kathrin Meyer; Louise R Rodino-Klapac; Scott Q Harper
Journal:  JCI Insight       Date:  2018-11-15

Review 5.  Genetic and epigenetic contributors to FSHD.

Authors:  Lucia Daxinger; Stephen J Tapscott; Silvère M van der Maarel
Journal:  Curr Opin Genet Dev       Date:  2015-09-07       Impact factor: 5.578

6.  A Pentanucleotide ATTTC Repeat Insertion in the Non-coding Region of DAB1, Mapping to SCA37, Causes Spinocerebellar Ataxia.

Authors:  Ana I Seixas; Joana R Loureiro; Cristina Costa; Andrés Ordóñez-Ugalde; Hugo Marcelino; Cláudia L Oliveira; José L Loureiro; Ashutosh Dhingra; Eva Brandão; Vitor T Cruz; Angela Timóteo; Beatriz Quintáns; Guy A Rouleau; Patrizia Rizzu; Ángel Carracedo; José Bessa; Peter Heutink; Jorge Sequeiros; Maria J Sobrido; Paula Coutinho; Isabel Silveira
Journal:  Am J Hum Genet       Date:  2017-07-06       Impact factor: 11.025

Review 7.  Emerging preclinical animal models for FSHD.

Authors:  Angela Lek; Fedik Rahimov; Peter L Jones; Louis M Kunkel
Journal:  Trends Mol Med       Date:  2015-03-20       Impact factor: 11.951

8.  Meeting Report: New Directions in the Biology and Disease of Skeletal Muscle 2014.

Authors:  Eugene J Wyatt; H Lee Sweeney; Elizabeth M McNally
Journal:  J Neuromuscul Dis       Date:  2014-01-01

9.  Genetic and epigenetic characteristics of FSHD-associated 4q and 10q D4Z4 that are distinct from non-4q/10q D4Z4 homologs.

Authors:  Weihua Zeng; Yen-Yun Chen; Daniel A Newkirk; Beibei Wu; Judit Balog; Xiangduo Kong; Alexander R Ball; Simona Zanotti; Rabi Tawil; Naohiro Hashimoto; Ali Mortazavi; Silvère M van der Maarel; Kyoko Yokomori
Journal:  Hum Mutat       Date:  2014-06-24       Impact factor: 4.878

Review 10.  Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.

Authors:  Amy E Campbell; Andrea E Belleville; Rebecca Resnick; Sean C Shadle; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.